Treatment of myoclonus-dystonia syndrome with tetrabenazine

Parkinsonism and Related Disorders

Volumn 20, Issue 12, 2014, Pages 1423-1426

  Luciano, Angelo Y ^a   Jinnah, H A ^b   Pfeiffer, Ronald F ^a   Truong, Daniel D ^c   Nance, Martha A ^d   LeDoux, Mark S ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Parkinson's and Movement Disorder Institute   (United States)

^d Struthers Parkinson's Center   (United States)

Author keywords

Blinded; Dopamine; Dystonia; Myoclonus; Tetrabenazine

Indexed keywords

DILTIAZEM; MOMETASONE FUROATE; MONTELUKAST; OMEPRAZOLE; TETRABENAZINE; ADRENERGIC RECEPTOR AFFECTING AGENT; CHAPERONE; TOR1A PROTEIN, HUMAN;

ADULT; ARTICLE; ASTHMA; CASE REPORT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG RESPONSE; DYSTONIA; EXON; FAHN MARSDEN RATING SCALE; FEMALE; GASTROESOPHAGEAL REFLUX; GENE; GENE DELETION; GENE MUTATION; GENOTYPE; GLOBAL DYSTONIA RATING SCALE; HANDWRITING; HUMAN; HYPERTENSION; MALE; MOTOR PERFORMANCE; MYOCLONUS; MYOCLONUS DYSTONIA; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SGCE GENE; SIBLING; UNIFIED MYOCLONUS RATING SCALE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DYSTONIC DISORDERS; GENETICS; MULTICENTER STUDY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADRENERGIC UPTAKE INHIBITORS; ADULT; DOUBLE-BLIND METHOD; DYSTONIC DISORDERS; FEMALE; HUMANS; MOLECULAR CHAPERONES; SEVERITY OF ILLNESS INDEX; TETRABENAZINE;

EID: 84916208035     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.09.029     Document Type: Article

References (15)

1. Peall K.J., Smith D.J., Kurian M.A., Wardle M., Waite A.J., Hedderly T., et al. SGCE mutations cause psychiatric disorders: clinical and genetic characterization. Brain 2013, 136:294-303.
2. Xiao J., Nance M.A., LeDoux M.S. Incomplete nonsense-mediated decay facilitates detection of a multi-exonic deletion mutation in SGCE. Clin Genet 2013, 84:276-280.
3. Nardocci N., Zorzi G., Barzaghi C., Zibordi F., Ciano C., Ghezzi D., et al. Myoclonus-dystonia syndrome: clinical presentation, disease course, and genetic features in 11 families. Mov Disord 2008, 23:28-34.
4. Rughani A.I., Lozano A.M. Surgical treatment of myoclonus dystonia syndrome. Mov Disord 2013, 28:282-287.
5. Frucht S.J., Leurgans S.E., Hallett M., Fahn S. The unified myoclonus rating scale. Adv Neurol 2002, 89:361-376.
6. Jankovic J., Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997, 48:358-362.
7. Kenny C., Hunter C., Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007, 22:193-197.
8. Derangula V.R., Pilli N.R., Nadavala S.K., Adireddy V., Inamadugu J.K., Ponnneri Liquid chromatography-tandem mass spectrometric assay for the determination of tetrabenazine and its active metabolites in human plasma: a pharmacokinetic study. Biomed Chromatogr 2013, 27:792-801.
9. Yokoi F., Dang M.T., Li J., Li Y. Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon-sarcoglycan deficient mice. JBiochem 2006, 140:141-146.
10. Ritz K., Van Schaik B.D., Jakobs M.E., Van Kampen A.H., Aronica E., Tijssen M.A., et al. SGCE isoform characterization and expression in human brain: implications for myoclonus-dystonia pathogenesis?. Eur J Hum Genet 2011, 19:438-444.
11. Carbon M., Raymond D., Ozelius L., Saunders-Pullman R., Frucht S., Dhawan V., et al. Metabolic changes in DYT11 myoclonus-dystonia. Neurology 2013, 80:385-391.
12. Popa T., Milani P., Richard A., Hubsch C., Brochard V., Tranchant C., et al. The neurophysiological features of myoclonus-dystonia and differentiation from other dystonias. JAMA Neurol 2014, 71:612-619.
13. Bostan A.C., Dum R.P., Strick P.L. Cerebellar networks with the cerebral cortex and basal ganglia. Trends Cogn Sci 2013, 17:241-254.
14. McKeon T.W., Lorden J.F., Beales M., Oltmans G.A. Alterations in the noradrenergic projection to the cerebellum of the dystonic (dt) rat. Brain Res 1986, 366:89-97.
15. Levitt P., Lau C., Pylypiw A., Ross L.L. Central adrenergic receptor changes in the inherited noradrenergic hyperinnervated mutant mouse tottering. Brain Res 1987, 418:174-177.